Table 3 Association between PTH slope/residuals/mean and mortality, by region
Exposure | Europe + Australia/NZ | Japan | North America | |||
|---|---|---|---|---|---|---|
N (%) | Adjusted* HR (95% CI) | N (%) | Adjusted* HR (95% CI) | N (%) | Adjusted* HR (95% CI) | |
PTH slope (% change per month) | ||||||
 Decreased > 15% | 487 (8%) | 1.08 (0.85–1.37) | 271 (10%) | 1.14 (0.72–1.80) | 1431 (8%) | 1.12 (0.97–1.30) |
 Decreased 5–15% | 1166 (20%) | 0.92 (0.77–1.09) | 566 (22%) | 1.25 (0.92–1.71) | 3747 (21%) | 1.10 (1.00–1.21) |
 No change ±5% | 2375 (40%) | 1 (Ref.) | 1152 (44%) | 1 (Ref.) | 7249 (40%) | 1 (Ref.) |
 Increased 5–15% | 1244 (21%) | 1.05 (0.91–1.21) | 443 (17%) | 0.81 (0.56–1.18) | 4063 (22%) | 1.07 (0.98–1.18) |
 Increased > 15% | 638 (11%) | 0.94 (0.75–1.17) | 195 (7%) | 1.57 (0.95–2.59) | 1761 (10%) | 1.11 (0.98–1.26) |
PTH mean squared residuals | ||||||
  < 0.01 | 991 (17%) | 1.09 (0.92–1.30) | 373 (14%) | 1.13 (0.75–1.72) | 1603 (9%) | 0.94 (0.81–1.10) |
 0.01–0.05 | 1576 (27%) | 0.95 (0.82–1.10) | 728 (28%) | 1.09 (0.78–1.53) | 3901 (21%) | 0.92 (0.83–1.02) |
 0.05–0.20 | 1833 (31%) | 1 (Ref.) | 901 (34%) | 1 (Ref.) | 6747 (37%) | 1 (Ref.) |
 0.20–0.50 | 920 (16%) | 0.91 (0.76–1.09) | 384 (15%) | 1.17 (0.74–1.88) | 3739 (20%) | 1.00 (0.91–1.11) |
  > 0.50 | 590 (10%) | 1.04 (0.83–1.31) | 241 (9%) | 1.22 (0.73–2.05) | 2261 (12%) | 0.94 (0.83–1.06) |
PTH geometric mean (pg/mL) | ||||||
  < 100 | 862 (15%) | 1.04 (0.86–1.25) | 983 (37%) | 1.22 (0.83–1.79) | 1130 (6%) | 0.97 (0.83–1.13) |
 100–199 | 1598 (27%) | 0.90 (0.76–1.05) | 1041 (40%) | 1.35 (0.93–1.97) | 3756 (21%) | 0.93 (0.84–1.02) |
 200–399 | 2120 (36%) | 1 (Ref.) | 514 (20%) | 1 (Ref.) | 8253 (45%) | 1 (Ref.) |
 400–599 | 774 (13%) | 1.23 (1.01–1.51) | 65 (2%) | – | 2827 (15%) | 1.04 (0.93–1.17) |
  ≥ 600 | 556 (9%) | 1.26 (0.97–1.62) | 24 (1%) | – | 2285 (13%) | 1.31 (1.14–1.50) |